Related Experiment Video
Updated: May 5, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Targetable driver gene-tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological
Wenqing Chen1, Fengyan Zhang2, Xin Zheng3
1Department of Internal Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Abstract:
Non-small cell lung cancer (NSCLC) is characterized by substantial molecular heterogeneity that critically influences the efficacy of immunotherapy. Although immune checkpoint inhibitors (ICIs) have improved outcomes in selected patients, responses vary markedly across molecular subtypes defined by targetable driver gene alterations. Increasing evidence indicates that oncogenic drivers, including EGFR, ALK, KRAS, MET, RET, and BRAF, actively shape the tumor immune microenvironment (TIME) by regulating antigen presentation, immune cell infiltration, cytokine signaling, metabolic programs, and immune checkpoint expression. These interactions generate distinct driver gene-associated immune phenotypes that underlie differential sensitivity and resistance to ICIs. Recent advances in single-cell and spatial profiling have further revealed the complexity and spatial organization of these immune landscapes. In this review, we summarize current mechanistic and clinical evidence supporting the targetable driver gene-TIME axis in NSCLC and discuss its implications for immunotherapy response, resistance, and patient stratification. This integrative framework provides a rationale for precision immunotherapy strategies and the design of biomarker-driven clinical trials.
Insights
Molecular subtypes of non-small cell lung cancer (NSCLC) significantly impact immunotherapy effectiveness. Oncogenic drivers shape the tumor immune microenvironment (TIME), influencing response to immune checkpoint inhibitors (ICIs).
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) exhibits significant molecular heterogeneity.
- Immune checkpoint inhibitors (ICIs) improve outcomes but responses vary by molecular subtype.
- Targetable driver gene alterations critically influence the tumor immune microenvironment (TIME).
Purpose of the Study:
- To review the mechanistic and clinical evidence linking targetable driver genes to the TIME in NSCLC.
- To discuss the implications of this axis for immunotherapy response and resistance.
- To highlight the role of this framework in patient stratification and clinical trial design.
Main Methods:
- Review of current mechanistic and clinical literature.
- Analysis of single-cell and spatial profiling data.
- Integration of genetic alterations, TIME characteristics, and ICI efficacy.
Main Results:
- Oncogenic drivers (e.g., EGFR, ALK, KRAS) actively modulate the TIME.
- Distinct driver gene-associated immune phenotypes correlate with differential ICI sensitivity and resistance.
- Advanced profiling techniques reveal complex spatial organization of immune landscapes.
Conclusions:
- The targetable driver gene-TIME axis is a critical determinant of immunotherapy outcomes in NSCLC.
- Understanding this axis supports precision immunotherapy strategies.
- Biomarker-driven clinical trials are essential for optimizing NSCLC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment